表紙
市場調查報告書
商品編碼
808276

GLP-1(Glucagon-Like Peptide-1)受體激動劑市場 - 成長,趨勢,預測(2019年∼2024年)

Glucagon like Peptide 1 (GLP - 1) Agonists Market - Growth, Trends, and Forecast (2019 - 2024)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

GLP-1(Glucagon-Like Peptide-1)受體激動劑市場在2019年到2024年間,預測將有很大的成長。這主要是由於GLP-1有效性的提高。

本報告提供全球GLP-1(Glucagon-Like Peptide-1)受體激動劑市場調查,市場概要,各醫藥品、各地區的市場規模的變化與預測,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查結果
  • 前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各類醫藥品
    • Exenatide
    • 利拉魯肽
    • Lixisenatide
    • Dulaglutide
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中南美
    • 中東、非洲

第6章 市場區隔

  • 第一型糖尿病的患者數
  • 第二型糖尿病的患者數

第7章 競爭情形

  • 企業簡介
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • AstraZeneca
  • 市場佔有率分析
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • AstraZeneca

第8章 市場機會與未來展望

目錄
Product Code: 62939

Market Overview

The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1.

Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people.

In addition, lowering birth rates, along with increasing life expectancy, in countries like Japan, Italy, Germany, and France which have a high percentage of the geriatric population, are expected to drive the growth of the market.Novo Nordisk Victoza held a 55% market share in the GLP-1 agonist market in 2017, but it is expected that Eli Lilly's Trulicity will dominate the market during the forecast period.

Scope of the Report

The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.

Key Market Trends - Constant Global Trend of High Diabetes Prevalence

The sales of GLP-1 are directly proportional to the global trend of high diabetes prevalence.

For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.

It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).

Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.

North America to Dominate the Market in Terms of Revenue

North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.

In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.

In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.

Competitive Landscape

The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all regions.

Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Teva confirmed generic Victoza and announced that it had filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), seeking approval to market the generic version of Novo Nordisk's Victoza® (liraglutide) injection, in the United States.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Exenatide
      • 5.1.1.1 Byetta (Value and Volume 2012-2024)
      • 5.1.1.2 Bydureon (Value and Volume 2012-2024)
    • 5.1.2 Liraglutide
      • 5.1.2.1 Victoza (Value and Volume 2012-2024)
    • 5.1.3 Lixisenatide
      • 5.1.3.1 Lyxumia (Value and Volume 2012-2024)
    • 5.1.4 Dulaglutide
      • 5.1.4.1 Trulicity (Value and Volume 2012-2024)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 US (Value and Volume 2012-2024)
      • 5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.1.2 Canada (Value and Volume 2012-2024)
      • 5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.1.3 Rest of North America (Value and Volume 2012-2024)
      • 5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    • 5.2.2 Europe
      • 5.2.2.1 Germany (Value and Volume 2012-2024)
      • 5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.2.2 Spain (Value and Volume 2012-2024)
      • 5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.2.3 Italy (Value and Volume 2012-2024)
      • 5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.2.4 France (Value and Volume 2012-2024)
      • 5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.2.5 UK (Value and Volume 2012-2024)
      • 5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.2.6 Russia (Value and Volume 2012-2024)
      • 5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
      • 5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 Japan (Value and Volume 2012-2024)
      • 5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.2 China (Value and Volume 2012-2024)
      • 5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.3 Australia (Value and Volume 2012-2024)
      • 5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.4 India (Value and Volume 2012-2024)
      • 5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.5 South Korea (Value and Volume 2012-2024)
      • 5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.6 Malaysia (Value and Volume 2012-2024)
      • 5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.7 Indonesia (Value and Volume 2012-2024)
      • 5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.8 Thailand (Value and Volume 2012-2024)
      • 5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.9 Philippines (Value and Volume 2012-2024)
      • 5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
      • 5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    • 5.2.4 Latin America
      • 5.2.4.1 Brazil (Value and Volume 2012-2024)
      • 5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.4.2 Mexico (Value and Volume 2012-2024)
      • 5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
      • 5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 South Africa (Value and Volume 2012-2024)
      • 5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
      • 5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.5.3 Oman (Value and Volume 2012-2024)
      • 5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.5.4 Egypt (Value and Volume 2012-2024)
      • 5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.5.5 Iran (Value and Volume 2012-2024)
      • 5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
      • 5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
      • 5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
      • 5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly
    • 7.1.4 AstraZeneca
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 Novo Nordisk
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly
    • 7.2.4 AstraZeneca

8 MARKET OPPORTUNITIES AND FUTURE TRENDS